Skip to content

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02811653
Acronym
TAMA
Enrollment
155
Registered
2016-06-23
Start date
2015-12-16
Completion date
2028-12-16
Last updated
2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

Motor slowing

Brief summary

In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.

Interventions

DEVICEBrain MRI
OTHERneuropsychological evaluation
BIOLOGICALBlood

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients * Age between 40 and 85 * French mother tongue * Consulting at the Amiens Memory Resource and Research Centre (CMRR) for: * MCI, according to Albert et al.'s criteria (Albert et al., 2011) * Mild dementia (MMSE\>20) due to AD, according to McKhann's criteria (McKhann et al., 2011). * Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005). * Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011). * Social security coverage * Healthy controls * Healthy age and gender matched volunteers will be recruited into the study from the general population.

Exclusion criteria

* Reading or writing difficulties related to a learning disorder or illiteracy. * A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure): * NYHA stage IV dyspnoea. * respiratory impairment requiring oxygen therapy. * liver impairment. * kidney failure, progressing neoplastic disease, or past or present alcohol abuse. * Past or present neurological disorders other than those having prompted consultation in the Memory Clinic: * stroke. * meningitis or encephalitis. * severe head injury. * sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments). * epilepsy (requiring ongoing treatment), * psychiatric disorders (other than treated depression). * treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state. * Impossibility to perform a neuropsychological evaluation or brain MRI. * Withdrawal from the study at any time, if desired. * Pregnancy * Contra-indication to MRI: * nerve stimulators * cochlear implants * ferromagnetic foreign bodies close to nervous structures in the eye or brain * cerebral shunts * dental appliances * Legal guardianship or incarceration.

Design outcomes

Primary

MeasureTime frame
median SRT (simple reaction time) to a stimulus (in milliseconds)Day 0

Countries

France

Contacts

CONTACTDaniela ANDRIUTA, PhD
andriuta.daniela@chu-amiens.fr+33 3 22 66 82 40
PRINCIPAL_INVESTIGATORDaniela ANDRIUTA, PhD

CHU Amiens

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026